Direct Inhibition of the YAP : TEAD Interaction: An Unprecedented Drug Discovery Challenge

Abstract

AbstractThe Hippo pathway, which is key in organ morphogenesis, is frequently deregulated in cancer. The TEAD (TEA domain family member) transcription factors are the most distal elements of this pathway, and their activity is regulated by proteins such as YAP (Yes‐associated protein). The identification of inhibitors of the YAP : TEAD interaction is one approach to develop novel anticancer drugs: the first clinical candidate (IAG933) preventing the association between these two proteins by direct competition has just been reported. The discovery of this molecule was particularly challenging because the interface between these two proteins is large (~3500 Å2 buried in complex formation) and made up of distinct contact areas. The most critical of these involves an omega‐loop (Ω‐loop), a secondary structure element rarely found in protein‐protein interactions. This review summarizes how the knowledge gained from structure‐function studies of the interaction between the Ω‐loop of YAP and TEAD was used to devise the strategy to identify potent low‐molecular weight compounds that show a pronounced anti‐tumor effect.